Two device recalls in under 60 days. A reported-injury count that climbed to 476 potential device reports, with 29 confirmed serious adverse events. Multiple investor class actions filed in federal court. And personal injury attorneys now actively investigating wrongful death claims on behalf of patients who suffered diabetic ketoacidosis, coma, or worse. The OmniPod 5 lawsuit landscape is moving fast — and for the millions of Type 1 diabetics who depend on Insulet’s tubeless patch pump, the stakes could not be higher.
What Is the OmniPod 5 and Why Does the Defect Matter?
The OmniPod 5 is a tubeless, wearable automated insulin delivery system manufactured by Insulet Corporation and used widely by people living with Type 1 diabetes. Unlike traditional insulin pumps, the OmniPod is a patch pump — meaning there is no external tubing connecting the pump body to the cannula inserted under the skin. Insulin flows entirely through internal components sealed inside a small, disposable pod worn directly on the body.
That design feature, which is central to OmniPod’s appeal, is also what makes the recalled defect so dangerous. When internal tubing tears inside the pod, insulin leaks within the device instead of entering the patient’s body. Because there is no external tubing to inspect and no visible sign of failure, users have no way to detect under-delivery without a device alert — and those alerts did not reliably trigger. A patient believing they are receiving their full insulin dose may instead be receiving none, silently drifting toward a life-threatening metabolic crisis.
The Centers for Disease Control and Prevention reports that approximately 2 million Americans live with Type 1 diabetes — a population almost entirely dependent on continuous insulin delivery. Any systemic failure in delivery technology carries mass-harm potential that extends far beyond a single patient.
The 2026 OmniPod Recalls: A Timeline of Escalating Failures
March 12, 2026: The First Recall and 18 Known Injuries
On March 12, 2026, Insulet Corporation issued a voluntary Medical Device Correction for certain OmniPod 5 pods after the company discovered a manufacturing defect — specifically, a small tear in internal tubing that causes insulin to leak inside the pod rather than being delivered to the patient. The result is under-delivery of insulin, a condition that can rapidly escalate into a metabolic emergency.
Six days later, on March 18, 2026, the U.S. Food and Drug Administration issued its own public safety alert warning that malfunctions associated with the defect could cause diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state, coma, and death. At the time of the March recall, Insulet had identified 18 serious adverse events linked to the manufacturing defect. Insulet’s stock fell $16.23 per share — a drop of 6.88% — following the March 13 announcement, closing at $219.84. Investors were shaken. Patients were alarmed. But the worst was still coming.
April 30 to May 2026: Injuries Surge, Second Recall Issued
On April 30, 2026, Insulet announced an expanded removal from use after the FDA had received 476 medical device reports potentially associated with the defect — a more than 26-fold increase from the original 18 adverse events reported at the time of the first recall. Importantly, regulators have clarified that those 476 filings represent potential device reports rather than confirmed cases; as of April 10, 2026, 29 serious adverse events had been confirmed. Even so, this figure almost certainly undercounts actual harm, as patients who experienced under-delivery and recovered without hospitalization may not have attributed the event to a device failure. No deaths have been confirmed in connection with the first recall as of the May 2026 FDA update.
Then in May 2026, Insulet issued a second, broader recall affecting approximately 7 million pods across the OmniPod 5, DASH, and Eros systems — dramatically widening the scope of the crisis beyond the original OmniPod 5 population. The May recall announcement sent Insulet’s stock down $7.79 per share, a 5.07% drop on May 27, 2026, compounding losses investors had already absorbed since the March announcement. For patients across multiple OmniPod product lines, the expanded recall raised urgent questions about whether any version of the device could be trusted to deliver insulin reliably.
The Securities Class Actions: What Investors Need to Know
The financial fallout from the dual recalls has triggered multiple investor class action lawsuits against Insulet Corporation in federal court. These cases allege that Insulet made materially false and misleading statements to investors regarding the safety and quality control of its devices during the period from February 21, 2025 through May 26, 2026 — and that when the truth emerged through the recalls and the surging adverse event count, investors suffered significant losses.
Several law firms have filed or are pursuing lead plaintiff status in these actions. The lead plaintiff deadline is August 31, 2026, meaning investors who purchased Insulet securities during the class period have until that date to move for appointment as lead plaintiff. Investors who purchased shares between February 21, 2025 and May 26, 2026 and suffered losses should consult with securities litigation counsel promptly, as the lead plaintiff deadline is firm.
Securities class actions of this type typically allege violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. Insulet is accused of concealing or downplaying known quality-control problems and failing to disclose the full extent of device failures — omissions that, plaintiffs allege, artificially inflated the stock price and caused investors to suffer losses when the recalls and injury data became public.
Personal Injury and Wrongful Death Investigations: What Patients and Families Need to Know
Parallel to the securities litigation, personal injury attorneys across the country are actively investigating product liability claims on behalf of OmniPod users who experienced insulin under-delivery and suffered serious harm. The injuries at the center of these investigations are severe: diabetic ketoacidosis requiring emergency hospitalization, hyperosmolar hyperglycemic state, loss of consciousness, coma, and death.
For patients and families, the legal theory is product liability — specifically, that Insulet placed a defective product into the stream of commerce, failed to adequately warn users of the known risk of internal tubing failure, and was negligent in its manufacturing quality controls. The expanded May 2026 recall, affecting approximately 7 million pods across three separate product systems, suggests the defect was not isolated to a narrow production batch but instead reflects a systemic failure with potentially wide-ranging patient impact.
Wrongful death claims are also under investigation. Attorneys representing families of patients who died following suspected insulin under-delivery events are gathering records to determine whether a device failure contributed to or caused the death. Because pod failures can mimic other causes of diabetic emergencies, medical and device records are critical to establishing causation. Families who lost a loved one using any OmniPod system — including the DASH and Eros platforms now covered by the May recall — should speak with an attorney before concluding that the death was unrelated to device failure.
How to Document Your OmniPod Injury Claim Starting Today
If you or a family member experienced a serious adverse event while using any OmniPod device — including OmniPod 5, DASH, or Eros — the steps you take now will directly affect the strength of any future claim. Evidence degrades quickly. Device data can be overwritten. Medical records must be formally requested. The following actions should be taken as soon as possible.
Preserve the pod. Do not discard the pod you were using at the time of the adverse event. Place it in a sealed bag and store it in a cool, dry location. Physical examination of the device by an expert may be critical to proving internal tubing failure.
Preserve all device data. OmniPod 5 syncs with a controller and, in many cases, with Insulet’s cloud platform. Request a full data export from Insulet immediately. This data logs insulin delivery commands, occlusion alerts, pod errors, and communication gaps — all of which may reveal a delivery failure that the device failed to flag in real time.
Request your complete medical records. Obtain emergency department records, hospital admission notes, laboratory results (particularly blood glucose, blood gas, and ketone levels), and any records documenting the treating physician’s assessment of the cause of your crisis. These records establish the severity of injury and, if properly documented, may connect the crisis to the device failure.
File an FDA MedWatch report. Reporting your adverse event to the FDA creates an official record and contributes to the agency’s ongoing safety surveillance. Reports can be submitted at FDA.gov/MedWatch.
Do not contact Insulet for a replacement without speaking to an attorney first. Accepting a replacement device or agreeing to any form of accommodation from Insulet without legal guidance may complicate your ability to pursue a claim.
Frequently Asked Questions About the OmniPod 5 Lawsuit
Who is eligible to file an OmniPod 5 lawsuit?
Any person who used a recalled OmniPod device — including OmniPod 5, DASH, or Eros pods — and suffered a serious adverse event such as diabetic ketoacidosis, hospitalization, coma, or another significant injury may have grounds for a personal injury claim. The May 2026 expanded recall, which covers approximately 7 million pods across all three systems, substantially broadens the pool of potentially affected users beyond OmniPod 5 alone. Family members of patients who died following a suspected insulin under-delivery event may also have wrongful death claims. Eligibility depends on the specific facts of each case, and an attorney consultation is the appropriate first step.
What injuries are linked to the OmniPod defect?
The defect — a tear in internal tubing that causes insulin to leak inside the pod rather than being delivered — can result in clinically dangerous insulin under-delivery. The FDA has identified diabetic ketoacidosis, hyperosmolar hyperglycemic state, coma, and death as potential consequences. As of April 10, 2026, 29 serious adverse events have been confirmed in connection with the recalls. The actual number of affected patients is likely higher, as not all under-delivery events result in emergency care or formal reporting.
Has an MDL been formed for OmniPod lawsuits yet?
As of mid-2026, no Multidistrict Litigation consolidation has been formally established for OmniPod personal injury cases. However, the combination of a dramatically expanded recall covering 7 million pods across three product lines, confirmed serious injuries, and active attorney investigations creates the conditions under which MDL petitions are typically filed. Plaintiffs’ attorneys are monitoring case filings, and consolidation remains a likely development as the litigation matures. Individuals who file claims early are better positioned regardless of whether an MDL is ultimately formed.
What is Insulet accused of in the securities class actions?
The investor class action lawsuits allege that Insulet made materially false or misleading statements about the safety and quality of its OmniPod devices during the period from February 21, 2025 through May 26, 2026. Plaintiffs allege that Insulet concealed known manufacturing defects and quality-control failures, causing its stock to trade at artificially inflated prices. When the recalls and the full scope of device failures became public — particularly the May 2026 announcement of an expanded recall covering 7 million pods — the stock dropped sharply, causing investor losses. The lead plaintiff deadline for these actions is August 31, 2026.
How long do I have to file an OmniPod 5 lawsuit?
Product liability statutes of limitations vary by state but typically range from two to four years from the date of injury or the date the injury was discovered. In wrongful death cases, the limitations period often runs from the date of death. Because the OmniPod recalls began in March 2026 and the expanded recall was issued in May 2026, the limitations clock is already running for many potential claimants. Waiting significantly increases the risk that evidence will be lost, witnesses will become unavailable, and legal options will narrow. Consulting with a personal injury attorney as soon as possible is strongly advised.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.